Dkt. 69395-A-PCT-US/JPW/JW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Vered Rosenberger, et al.

U.S. Serial No. : Not Yet Known (national stage of PCT

International Application No.

PCT/US2004/036172)

Filed : Herewith

For : NANOPARTICLES FOR DRUG DELIVERY

1185 Avenue of the Americas New York, New York 10036

April 27, 2006

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. \$1.56 and \$1.97(a)-(d), applicants request that the following documents be considered and made of record in the above-identified application which is listed on Form PTO-1449, attached hereto as **Exhibit A**:

- Almeida AJ, Rune S, and Müller RH. (1997) Peptide-loaded Solid Lipid Nanospheres. Int. J. Pharm. 149(2): 255-265 (abstract only) (Exhibit 1);
- 2. Cui Z and Mumper RJ. (2002) Genetic Immunization using Nanoparticles Engineered from Microemulsion Precursors. Pharm. Res. 19(7): 939-946 (Exhibit 2);
- 3. Cui Z and Mumper RJ. (2002) Coating of Cationized Protein on Engineered Nanoparticles Results in Enhanced Immune Responses. Int. J. Pharm. 238: 229-239 (Exhibit 3);
- 4. Cui Z and Mumper RJ. (2003) Microparticles and

Applicants: Vered Rosenberger, et AP12 Rec'd PCT/PTO ~ 7 APR 2006

Filed: Herewith

Page 2

Nanoparticles as Delivery Systems for DNA Vaccines.

Crit. Rev. Ther. Drug Carrier Syst. 20(2&3): 103-137

(Exhibit 4);

- 5. Lowe PJ and Temple CS. (1994) Calcitonin and Insulin in isobutylcyanoacrylate Nanocapsules: Protection against Proteases and Effect on Intestinal Absorption in Rats. J. Pharm. Pharmacol. 46(7): 547-552 (abstract only) (Exhibit 5);
- 6. Oyewumi MO and Mumper RJ. (2002) Engineering Tumor Targeted Gadolinium Hexanedione Nanoparticles for Potential Application in Neutron Capture Therapy.

 Bioconjug. Chem. 13(6): 1328-1335 (Exhibit 6);
- 7. Oyewumi MO and Mumper RJ. (2002) Gadolinium Loaded Nanoparticles Engineered from Microemulsion Templates.

 Drug Dev. Ind. Pharm. 28(3): 317-328 (abstract only)

 (Exhibit 7);
- 8. Sakuma S, Ishida Y, Sudo R, Suzuki N, Kikuchi H, Hiwatari K-I, Kishida A, Akashi M, and Hayashi M. Stabilization of Salmon Calcitonin by Polystyrene nanoparticles having Surface Hydrophilic polymeric Chains, Against Enzymatic Degradation. Int. J. Pharm. 159(2): 181-189 (Exhibit 8);
- 9. International Search Report issued by the International Searching Authority (ISA/US) on March 11, 2005 in connection with International Application No. PCT/US2004/036172 (Exhibit 9);
- 10. U.S. Patent No. 6,514,938 B1 (GAD et al.), published
 February 4, 2003 (Exhibit 10);
- 11. U.S. Patent No. 6,355,270 B1 (FERRARI et al.),
 published March 12, 2002 (Exhibit 11);

Applicants: Vered Rosenberger, et al P12 Rec'd PCT/PTO 27 APR 2006

Filed: Herewith

Page 3

12. U.S. Patent Application Publication No. 2004/0178388 A1 (MUMPER et al.), published September 16, 2004 (Exhibit 12);

- 13. U.S. Patent Application Publication No. 2005/0170004 A1 (ROSENBERGER et al.), published August 4, 2005 (Exhibit 13);
- International Searching 14. Written Opinion of the Authority issued by the International Searching Authority (ISA/US) on March 11, 2005 in connection with No. PCT/US2004/036172 International Application (Exhibit 14); and
- 15. International Preliminary Report on Patentability (Chapter II of the Patent Cooperation Treaty) issued by International Preliminary Examining Authority July 1, 2005 in connection (IPEA/US) on PCT/US2004/036172 International Application No. (Exhibit 15).

Copies of documents numbers 1-15 are attached hereto as Exhibits 1-15, respectively.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,

White

Registration No. 28,678 Attorney for Applicants Cooper & Dunham LLP

1185 Avenue of the Americas New York, New York 10036

(212) 278-0400

10/577182 IAP12 Rec'd PCT/PTO 27 APR 2006

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
Substitute for form 1449/PTO	Application Number	NOT YET KNOWN
INFORMATION DISCLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT	First Named Inventor	Vered Rosenberger
(lanca many sharts as assessment	Art Unit	
(Use as many sheets as necessary)	Examiner Name	
Sheet 1 of 3	Attorney Docket Number	69395-A-PCT-US/JPW/JW

		NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Almeida AJ, Rune S, and Müller RH. (1997) Peptide-loaded Solid Lipid Nanospheres. Int. J. Pharm. 149(2): 255-265 (abstract only)	
	2	Cui Z and Mumper RJ. (2002) Genetic Immunization using Nanoparticles Engineered from Microemulsion Precursors. <i>Pharm. Res.</i> 19(7): 939-946	
	3	Cui Z and Mumper RJ. (2002) Coating of Cationized Protein on Engineered Nanoparticles Results in Enhanced Immune Responses. Int. J. Pharm. 238: 229-239	
	4	Cui Z and Mumper RJ. (2003) Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines. Crit. Rev. Ther. Drug Carrier Syst. 20(2&3): 103-137	
	5	Lowe PJ and Temple CS. (1994) Calcitonin and Insulin in isobutylcyanoacrylate Nanocapsules: Protection against Proteases and Effect on Intestinal Absorption in Rats. <i>J. Pharm. Pharmacol.</i> 46(7): 547-552 (abstract only)	
	6	Oyewumi MO and Mumper RJ. (2002) Engineering Tumor Targeted Gadolinium Hexanedione Nanoparticles for Potential Application in Neutron Capture Therapy. <i>Bioconjug. Chem.</i> 13(6): 1328-1335	
	7	Oyewumi MO and Mumper RJ. (2002) Gadolinium Loaded Nanoparticles Engineered from Microemulsion Templates. <i>Drug Dev. Ind. Pharm.</i> 28(3): 317-328 (abstract only)	
	8	Sakuma S, Ishida Y, Sudo R, Suzuki N, Kikuchi H, Hiwatari K-I, Kishida A, Akashi M, and Hayashi M. Stabilization of Salmon Calcitonin by Polystyrene nanoparticles having Surface Hydrophilic polymeric Chains, Against Enzymatic Degradation. Int. J. Pharm. 159(2): 181-189	
	9	International Search Report issued by the International Searching Authority (ISA/US) on March 11, 2005 in connection with International Application No. PCT/US2004/036172	
	14	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) on March 11, 2005 in connection with International Application No. PCT/US2004/036172	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Vered Rosenberger, et al. U.S. Serial No. NOT YET KNOWN Filed: Herewith (as §371 national stage of PCT/US2004/036172) Exhibit A

EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/577182 IAP12 Rec'd PCT/PTO 27 APR 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number NOT YET KNOWN Filing Date Herewith INFORMATION DISCLOSURE First Named Inventor Vered Rosenberger STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessary) **Examiner Name** Attorney Docket Number 69395-A-PCT-US/JPW/JW Sheet |2

U. S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (4 known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	 	Number-Kind Code		12	- I gares Appear		
	10	^{US-} 6,514,938 B1	02-04-2003	GAD et at.			
	11	^{US-} 6,355,270 B1	03-12-2002	FERRARI et al.			
	12	^{US-} 2004/0178388 A1	09-16-2004	MUMPER et al.			
	13	^{US-} 2005/0170004 A1	08-04-2005	ROSENBERGER et al.			
		US-					
	-	US-					
		US-					
		US-					
		US-					
		US-					
-		US-					
-		US-					
		US-					
		US-					
		US-					
		US-					
	-	US-					
		US-					
		US-			-		

	FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶	
						H	
						Ш	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND** TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10/577182

IAP12 Rec'd PCT/PTO 27 APR 2006

PTO/SB/08B (07-05)

•	Approved for use through 07/31/2006, OMB 0651-003
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Lindan the Conservate Deduction Act of 1005	no personal are considered to a serior of the serior of information unless it as a first constitution of the serior of the serio

Substitute for form 1449/PTO		e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
		Application Number	NOT YET KNOWN	
INFORMAT	TION DIS	CLOSURE	Filing Date	Herewith
STATEMENT BY APPLICANT		First Named Inventor	Vered Rosenberger	
			Art Unit	
(Use as n	nany sheets as n	ecessary)	Examiner Name	
Sheet 3	of	3	Attorney Docket Number	69395-A-PCT-US/JPW/JW

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	15	International Preliminary Report on Patentability (Chapter II of the Patent Cooperation Treaty) issued by the International Preliminary Examining Authority (IPEA/US) on July 1, 2005 in connection with International Application No. PCT/US2004/036172			
	:	·			

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.